本頁面由Tiger Trade Technology Pte. Ltd.提供服務

武田製藥

18.66
0.0000
盤後18.660.00000.00%17:55 EST
成交量:200.08萬
成交額:3,726.36萬
市值:589.50億
市盈率:83.03
高:18.70
開:18.61
低:18.52
收:18.66
52周最高:18.79
52周最低:12.99
股本:31.59億
流通股本:30.57億
量比:0.68
換手率:0.07%
股息:0.64
股息率:3.42%
每股收益(TTM):0.2247
每股收益(LYR):0.2245
淨資產收益率:1.50%
總資產收益率:2.47%
市淨率:1.20
市盈率(LYR):83.13

資料載入中...

公司資料

公司名字:
武田製藥
交易所:
NYSE
成立時間:
1781
員工人數:
47455
公司地址:
1-1, Nihonbashi-Honcho 2-chome,Chuo-ku,Tokyo,Tokyo,Japan
郵編:
103-8668
傳真:
81 3 3278-2000
簡介:
Takeda Pharmaceutical Company Limited是一家在日本註冊成立的上市公司成立於1925年1月12日。該公司及其子公司是一家主要的全球製藥集團,從事醫藥產品、非處方藥和准藥品消費品以及其他醫療保健產品的研究、開發、製造和營銷。武田的主要醫藥產品包括以下治療領域的藥物:胃腸病學、腫瘤學和神經科學。

董事

名稱
職位
Christophe Weber
Representative Director, President and Chief Executive Officer
Andrew S. Plump
Director and President, Research and Development
Emiko Higashi
External Director
Ian Clark
External Director
Jean Luc Butel
External Director
John Maraganore
External Director
Kimberly A. Reed
External Director
Koji Hatsukawa
External Director
Masami Iijima
External Director and Chair of the Board
Michel Orsinger
External Director
Miki Tsusaka
External Director
Milano Furuta
Director and Chief Financial Officer
Steven Gillis
External Director
Yoshiaki Fujimori
External Director

股東

名稱
職位
Christophe Weber
Representative Director, President and Chief Executive Officer
Milano Furuta
Director and Chief Financial Officer
Akiko Amakawa
Corporate Strategy Officer & CEO Chief of Staff
Asuka Miyabashira
President, Japan Pharma Business Unit
Elaine Shannon
Global Quality Officer
Gabriele Ricci
Chief Data and Technology Officer
Giles Platford
President, Plasma-Derived Therapies Business Unit
Julie Kim
Interim President, Global Portfolio Division,President, U.S. Business Unit and U.S. Country Head
Lauren Duprey
Chief Human Resources Officer
Marcello Agosti
Global Business Development Officer
Mwana Lugogo
Chief Ethics and Compliance Officer
Natalie Furney
Global General Counsel
Takako Ohyabu
Chief Global Corporate Affairs & Sustainability Officer
Teresa Bitetti
President, Global Oncology Business Unit
Thomas Wozniewski
Global Manufacturing and Supply Officer